Market News & Trends
Vasomune Therapeutics & AnGes, Inc. Enter Multi-Million Dollar Global Co-Development Agreement
Vasomune Therapeutics and AnGes, Inc. recently announced the signing of an innovative global co-development agreement for the development and commercialization of therapeutics treating diseases associated…
Cantabio Pharmaceuticals to Present Positive In Vivo Efficacy Results
Cantabio Pharmaceuticals Inc. recently announced that Dr. Gergely Toth, Cantabio's CEO, will present results from the company's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic…
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
Moleculin Biotech, Inc. recently announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults.…
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA
ARCA Biopharma, Inc. recently announced it has received guidance from the US FDA following an End-of-Phase 2 meeting regarding the Phase 3 program for ARCA’s…
BioPharmX Receives IRB Approval to Initiate Phase 2 Trial
BioPharmX Corporation recently announced it has received Institutional Review Board approval for its Phase 2 study of BPX-04 for the treatment of papulopustular rosacea. The…
Baxter Announces Health Canada Approval of Spectrum IQ Infusion System
Baxter Canada recently announced Health Canada approval for the Spectrum IQ Infusion System with Dose IQ Safety Software. The Spectrum IQ system features new bi-directional electronic medical records (EMR) integration to help…
Croda Invests in SiSaf’s Novel Bio-Courier Technology
Croda International Plc and SiSaf Ltd recently announced an exciting new strategic partnership. Croda, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has agreed a commercial arrangement with SiSaf, a pioneering UK-based biopharmaceutical company.
Microfluidic Modulation Spectroscopy (MMS) For Protein Therapeutic Drug Analysis
Automated, high sensitivity spectroscopic analyses for the development, formulation and manufacture of biotherapeutics are now available thanks to RedShiftBio’s new AQS3pro protein characterization platform. The system is based on Microfluidic Modulation Spectroscopy (MMS) technology. Read this application note to learn about how MMS characterizes higher order protein structures, the mechanisms of protein stability, aggregation, protein similarity and quantitation.
ABITEC Corporation & DKSH Announce Specialty Lipid Distribution Agreement
ABITEC Corporation, a global manufacturer of specialty lipids, has executed a multi-year agreement with distribution partner DKSH to market and sell its ingredients into select…
Translate Bio Announces Closing of Collaboration & Licensing Agreement with Sanofi Pasteur
Translate Bio recently announced the closing of a previously announced research collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to…
WuXi Biologics & Immune Pharmaceuticals Announce Late-Phase Development & Manufacturing Partnership
WuXi Biologics and Immune Pharmaceuticals recently announced a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed…
FDA Grants Fast-Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor
Aclaris Therapeutics, Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3…
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen in combination with FluMist…
Aurin Biotech Awarded US Patent for Cancer Drug
Aurin Biotech’s ATAC, a drug which has successfully halted the growth of cancerous tumors, was recently awarded a patent (10,004,707 B2) by the United States…
Catalent Biologics Adopts Berkeley Lights’ Beacon Optofluidic Platform
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, and Berkeley Lights, Inc.…
Axovant Announces Global Licensing Agreement With Benitec Biopharma
Axovant Sciences recently announced it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal…
Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial
Zynerba Pharmaceuticals, Inc. recently announced the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with…
Endocyte & ITM Announce Long-Term Supply Agreement
Endocyte, Inc. and ITM Isotopen Technologien München AG recently announced that ITM´s subsidiary, Isotope Technologies Garching GmbH (ITG), and Endocyte have signed a long-term global…
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd.
iBio, Inc. recently announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities…
Codexis Doses First Subjects in Phase 1a Trial; Triggers Milestone
Codexis, Inc. recently announced it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being…
